Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

AlzeCure Pharma’s CEO Martin Jönsson.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

More on the new study.

Stockholm region’s only GameTech hub is being built in Flemingsberg

In September this year, Press Start took the next step in developing the Stockholm region’s GameTech ecosystem. Since then, the community has continued to grow, more studios have joined, and work on the next major initiative has gained momentum. So, what has happened so far, and what comes next?

CSIB: New interdisciplinary center brings research together to tackle future infectious threats

Center for Systems Infection Biology (CSIB) was recently inaugurated at Campus Flemingsberg. The new interdisciplinary initiative brings together research, advanced infrastructure and expertise to deepen the understanding of infectious diseases and accelerate the path from research to clinical application. We met with Director Ujjwal Neogi and Co-director Iva Filipovic to talk about the center’s goals, its strong focus on collaboration, and its ambition to contribute to pandemic preparedness.

Vecura – 30 Years Dedicated to the Medicine of the Future

In Flemingsberg, pioneers have helped shape the medicine of the future since 1996. This year, the manufacturing unit Vecura celebrates 30 years of supporting the development of cell and gene therapies – advanced therapies that enable more personalized treatments. We spoke with Pontus Blomberg, strategic advisor and former Director of Operations, who has helped build one of Sweden’s leading laboratories in the field.

2023-06-22T12:22:38+02:00
Go to Top